Skip navigation

Current DateTime: 03:32:07 16 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 03:32:07 16 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 03:32:07 16 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Merck KGaA Profit Rises, Slightly Misses Expectations
By: Reuters | 23 Jul 2008 | 01:53 AM ET
Text Size

German drugs and chemicals company Merck KGaA reported a 15 percent rise in second-quarter operating profit on Wednesday thanks to rising sales of liquid crystals and multiple-sclerosis and cancer drugs.

Operating profit rose to 320.5 million euros ($510 million) from 277.5 million euros a year earlier, slightly missing the average estimate of 326 million euros in a Reuters poll of 15 analysts.

"Currency effects continued to have a considerable negative impact on total revenues," the company said in a statement.

Merck KGaA said total revenues grew organically by 12 percent but this was reduced by 6.1 percentage points due to translation of local currencies into the strong euro.

Sales of its cancer medicine Erbitux rose 24 percent in the second quarter, while sales of its multiple-sclerosis drug Rebif increased 2.8 percent.

Merck KGaA is also the world's largest supplier of the liquid crystal compounds used in televisions, mobile phones and computer laptops.

Liquid crystals sales rose 7 percent to 238 million euros, despite negative currency effects.

The operating profit margin for this business dipped to 45 percent in the quarter.

For 2008, Merck reiterated it expected group revenue to grow 5-9 percent and its operating margin -- excluding amortization and integration costs -- to be 23-27 percent.

Merck KGaA shares have fallen about 10 percent this year, roughly in line with the pan-European DJ Stoxx chemicals index and the drugs sector index, partly on worries over the impact of a slowdown in the U.S. economy.

According to Reuters data, Merck shares trade at 16 times estimated 2009 profit, a premium to the chemicals and drugs sectors' 12 times thanks partly to upbeat outlook for Erbitux.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
ADD COMMENTS
Remaining characters


Current DateTime: 01:58:09 16 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:58:09 16 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:38:26 16 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:38:26 16 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters